Credit Suisse raises PT for Iveric Bio as eye therapy data expected sooner

IVERIC bio

05/05/2022 11:56

** Credit Suisse raises PT for drug developer  ISEE.O  by $1
to $22 as company moves up timing for reporting data from eye
disorder study
    ** Co expects to report topline data from second late-stage
study of its eye disorder therapy in Q3 vs prior guidance of H2
of 2022
    ** Zimura is co's experimental drug for an eye disorder
called geographic atrophy
    ** Geographic atrophy is an advanced form of dry age-related
macular degeneration, in which cells in the retina waste away
    ** Stock down ~10.6% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))